Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Assets (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Assets for 11 consecutive years, with $296.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets fell 31.86% to $296.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $296.4 million, a 31.86% decrease, with the full-year FY2025 number at $296.4 million, down 31.86% from a year prior.
  • Assets was $296.4 million for Q4 2025 at Cartesian Therapeutics, down from $372.7 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $455.3 million in Q3 2024 to a low of $106.0 million in Q3 2023.
  • A 5-year average of $254.9 million and a median of $184.3 million in 2021 define the central range for Assets.
  • Peak YoY movement for Assets: crashed 40.52% in 2023, then soared 329.41% in 2024.
  • Cartesian Therapeutics' Assets stood at $159.9 million in 2021, then grew by 3.75% to $165.9 million in 2022, then surged by 83.89% to $305.0 million in 2023, then skyrocketed by 42.61% to $435.0 million in 2024, then plummeted by 31.86% to $296.4 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Assets are $296.4 million (Q4 2025), $372.7 million (Q3 2025), and $388.9 million (Q2 2025).